Centre for Virus and Vaccine Research, Sunway University, 5, Jalan Universiti, 47500, Bandar Sunway, Selangor, Malaysia.
J Biomed Sci. 2021 Jan 15;28(1):10. doi: 10.1186/s12929-021-00708-8.
Viruses from the genus Enterovirus (EV) of the Picornaviridae family are known to cause diseases such as hand foot and mouth disease (HFMD), respiratory diseases, encephalitis and myocarditis. The capsid of EV is an attractive target for the development of direct-acting small molecules that can interfere with viral entry. Some of the capsid binders have been evaluated in clinical trials but the majority have failed due to insufficient efficacy or unacceptable off-target effects. Furthermore, most of the capsid binders exhibited a low barrier to resistance. Alternatively, host-targeting inhibitors such as peptides derived from the capsid of EV that can recognize cellular receptors have been identified. However, the majority of these peptides displayed low anti-EV potency (µM range) as compared to the potency of small molecule compounds (nM range). Nonetheless, the development of anti-EV peptides is warranted as they may complement the small-molecules in a drug combination strategy to treat EVs. Lastly, structure-based approach to design antiviral peptides should be utilized to unearth potent anti-EV peptides.
肠道病毒属病毒属于小 RNA 病毒科的肠道病毒属，已知可引起手足口病（HFMD）、呼吸道疾病、脑炎和心肌炎等疾病。肠道病毒的衣壳是开发可干扰病毒进入的直接作用小分子的有吸引力的靶标。一些衣壳结合物已在临床试验中进行了评估，但由于疗效不足或不可接受的脱靶效应，大多数衣壳结合物都失败了。此外，大多数衣壳结合物表现出对耐药性的低屏障。或者，已经鉴定出可以识别细胞受体的来自肠道病毒衣壳的肽等宿主靶向抑制剂。然而，与小分子化合物（纳摩尔范围）的效力相比，这些肽中的大多数对 EV 的抗效力（µM 范围）较低。尽管如此，开发抗 EV 肽是合理的，因为它们可以在药物联合治疗策略中与小分子互补，以治疗 EV。最后，应该利用基于结构的方法来设计抗病毒肽，以发现有效的抗 EV 肽。
